Connection

CHENG CAMERON YIN to Mutation

This is a "connection" page, showing publications CHENG CAMERON YIN has written about Mutation.
Connection Strength

0.788
  1. STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2024 06 01; 109(6):1825-1835.
    View in: PubMed
    Score: 0.230
  2. The prevalence of CGG repeat expansion mutation in FMR1 gene in the northern Chinese women of reproductive age. BMC Med Genet. 2019 05 16; 20(1):81.
    View in: PubMed
    Score: 0.162
  3. A novel mutation in HAUS7 results in severe oligozoospermia in two brothers. Gene. 2018 Jan 10; 639:106-110.
    View in: PubMed
    Score: 0.145
  4. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102.
    View in: PubMed
    Score: 0.049
  5. Whole-exome sequencing as a powerful tool for identifying genetic causes in a patient with POLG-related disorders and phenylketonuria. J Int Med Res. 2019 Mar; 47(3):1387-1394.
    View in: PubMed
    Score: 0.040
  6. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3.
    View in: PubMed
    Score: 0.026
  7. Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study. Arch Pathol Lab Med. 2011 Aug; 135(8):994-1000.
    View in: PubMed
    Score: 0.024
  8. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 2010 Sep; 101(9):2005-10.
    View in: PubMed
    Score: 0.022
  9. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007 Dec 01; 110(12):4005-11.
    View in: PubMed
    Score: 0.018
  10. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. Mod Pathol. 2007 Jan; 20(1):1-7.
    View in: PubMed
    Score: 0.017
  11. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia. Am J Clin Pathol. 2005 Jun; 123(6):840-8.
    View in: PubMed
    Score: 0.015
  12. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):686-92.
    View in: PubMed
    Score: 0.007
  13. MYC/BCL2 double-hit high-grade B-cell lymphoma. Adv Anat Pathol. 2013 Sep; 20(5):315-26.
    View in: PubMed
    Score: 0.007
  14. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013 Jan; 54(1):138-44.
    View in: PubMed
    Score: 0.006
  15. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings. Am J Clin Pathol. 2011 Mar; 135(3):398-403.
    View in: PubMed
    Score: 0.006
  16. Trisomy 14 as a sole chromosome abnormality is associated with older age, a heterogenous group of myeloid neoplasms with dysplasia, and a wide spectrum of disease progression. J Biomed Biotechnol. 2010; 2010:365318.
    View in: PubMed
    Score: 0.006
  17. HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod Pathol. 2010 Mar; 23(3):381-91.
    View in: PubMed
    Score: 0.005
  18. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol. 2008 Jul; 142(1):36-44.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.